Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1601-1620 of 3,900 trials

Advanced Solid Tumors: ANV600 and Pembrolizumab Study

We are testing a new treatment, ANV600, alone and with pembrolizumab for people with advanced solid tumors. The goal is to evaluate safety and how well it may help fight cancer.

Advanced Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Psoriasis Management: Proactive Drug Monitoring Study

We are comparing proactive drug monitoring to standard care for people with moderate to severe psoriasis. The goal is to see if proactive monitoring helps maintain better disease control and improves quality of life.

Moderate-to-Severe Psoriasis1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesAllergologyDermatology

Peripheral T Cell Lymphoma: LIS1 Antibody Study

We are testing a new antibody treatment for patients with relapsed or refractory peripheral T cell lymphoma. The study aims to evaluate its safety and effectiveness in fighting this type of cancer.

Peripheral T-cell Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Cholesterol Management: Rosuvastatin 10 mg

We are examining whether a new formulation of Rosuvastatin 10 mg works the same as the current version for managing cholesterol levels. This study is for individuals who need cholesterol-lowering treatment.

Healthy Volunteers6-12 monthsSafety phase (I)CardiologyInternal Medicine

ADP-TILIL7: New Treatment Study

We are exploring a new treatment for patients with specific health conditions. Our goal is to understand its effects and potential benefits compared to existing therapies.

Advanced Melanoma>2 yearsSafety phase (I)Oncology

Radiprodil for Children with GRIN-related Disorder

We are studying a new medication to see if it is safe and helps reduce seizures and improve behavior in children with GRIN-related disorder. This trial aims to find the right dose and understand its effects over time.

GRIN-related Disorder>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesNeurologyPediatrics

High-Risk Neuroblastoma: Dinutuximab Beta with Chemotherapy

We are studying the safety and effectiveness of combining dinutuximab beta with two chemotherapy regimens for children with newly diagnosed high-risk neuroblastoma. This research aims to improve treatment options and outcomes for these young patients.

Neuroblastoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesHematologyOncologyPediatrics

Alzheimer's Disease: RO7126209 IV Treatment Study

We are investigating a new intravenous medication for individuals with mild to moderate Alzheimer's disease. The study aims to assess its safety and how it affects the brain over multiple doses.

Alzheimer's Disease>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteNeurologyPsychiatry

Solid Tumors: PYX-201 Treatment Study

We are testing a new drug, PYX-201, for patients with solid tumors. This study aims to understand its safety and how it may work in treating cancer.

Advanced Solid TumorsSafety phase (I)Oncology

Ulcerative Colitis: Tofacitinib for Children

We are studying whether the oral medication tofacitinib can help children with moderately to severely active ulcerative colitis achieve remission. The trial will also look at how well the medication works and how it is accepted by young patients.

Ulcerative Colitis1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

Ponatinib for Pediatric Leukemias and Solid Tumors

We are studying the safety and effectiveness of ponatinib in children with recurrent or hard-to-treat leukemias and solid tumors. This trial aims to help those who have not responded to other therapies.

Acute Myeloid LeukaemiaChronic Myeloid Leukaemia1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

Sepsis Treatment: Meropenem vs. Piperacillin/Tazobactam

We are comparing two antibiotics to see which one may help critically ill adults with sepsis survive better and improve their health outcomes.

Septic ShockSepsis6-12 monthsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesInternal Medicine

Heart Failure: Vicadrostat and Empagliflozin Study

We are testing if the combination of vicadrostat and empagliflozin helps people with heart failure feel better and reduces serious heart-related events. This study is for individuals with specific heart failure symptoms and heart function.

Heart FailureConfirmation phase (III)Investigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Narsoplimab for Children with High-Risk Stem Cell Transplant Complications

We are studying whether narsoplimab can improve survival and safety in children with thrombotic microangiopathy after stem cell transplants. This trial will help us understand how well this treatment works and its effects on young patients.

Thrombotic Microangiopathy1-2 yearsEfficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementHematologyPediatrics

Fabry Disease: Venglustat Tablets

We are studying whether venglustat can improve heart health in adults with Fabry disease compared to standard treatments. The trial also looks at its effects on kidney function and overall well-being.

Fabry's Disease1-2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCardiologyHematologyInternal Medicine

Atrial Fibrillation: New Drug Treatment After Stent Surgery

We are studying whether a simpler medication regimen can safely prevent blood clots and serious heart issues in patients with irregular heartbeat after coronary stent implantation. This trial compares it to the current standard treatment involving multiple medications.

Acute Coronary SyndromeAtrial FibrillationAtrial Flutter>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Constipation Prevention in Critically Ill Children: PEG3350+E Treatment

We are studying whether a special solution can help prevent constipation in critically ill children. The trial also looks at the safety of this treatment and compares stool consistency in different patient groups.

Constipation≤3 monthsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyPediatrics

CART Cell Therapy for Acute Lymphoblastic Leukemia in Young Patients

We are studying the safety and feasibility of new CART cell therapies for children and young adults with relapsed or refractory acute lymphoblastic leukemia. This trial aims to find better treatment options for those who have not responded to current therapies.

Acute Lymphoblastic Leukemia (ALL)>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesHematologyOncology

Burning Mouth Syndrome: Clonazepam Treatment Study

We are exploring how a topical treatment with clonazepam affects pain and other symptoms in people with burning mouth syndrome. The study will also look at patient preferences and experiences with the treatment over time.

Burning Mouth Syndrome6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesOtolaryngologyPsychiatry

Pulmonary Aspergillosis: MIRAGE Imaging Study

We are testing a new imaging method using a radioactive substance to see if it helps visualize lung infections caused by Aspergillus. This study aims to improve diagnosis and understanding of this condition.

Pulmonary AspergillosisEfficacy phase (II)No PlaceboStandard MedicinesInfectious DiseasesPulmonology